ISIS Pharmaceuticals, Inc. Stock Nasdaq
Stocks
US4643301090
Biotechnology & Medical Research
| Market Cap | 9.06B 7.83B 7.31B 6.71B 12.62B 862B 12.82B 85.82B 33.68B 432B 34B 33.26B 1,428B | P/E 2026 * |
-15.2x | P/E 2027 * | -29.5x |
|---|---|---|---|---|---|
| Enterprise Value | 8.66B 7.49B 7B 6.42B 12.07B 824B 12.26B 82.07B 32.21B 413B 32.52B 31.81B 1,366B | EV / Sales 2026 * |
9.41x | EV / Sales 2027 * | 6.29x |
| Free-Float |
99.09% | Yield 2026 * |
-
| Yield 2027 * | - |
Last Transcript: ISIS Pharmaceuticals, Inc.
| 1 day | +1.33% |
| Manager | Title | Age | Since |
|---|---|---|---|
D. Walke
IRC | Investor Relations Contact | 60 | 01/07/2012 |
Brett Monia
CEO | Chief Executive Officer | 64 | 01/01/2020 |
Elizabeth Hougen
DFI | Director of Finance/CFO | 64 | 01/05/2000 |
| Director | Title | Age | Since |
|---|---|---|---|
Joseph Klein
BRD | Director/Board Member | 64 | 13/12/2005 |
| Director/Board Member | 73 | 01/05/2002 | |
Brett Monia
BRD | Director/Board Member | 64 | 25/03/2019 |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | +1.33% | +2.73% | - | - | 9.06B | |
| +0.99% | +1.78% | +4.07% | +16.73% | 48.7B | |
| +2.07% | +7.83% | +478.60% | +582.25% | 42.05B | |
| +1.78% | +0.83% | +32.43% | +8.06% | 38.26B | |
| +4.59% | +9.20% | +15.69% | +84.03% | 37.5B | |
| +2.21% | +4.89% | +17.24% | +51.64% | 31.44B | |
| +2.35% | +4.69% | - | - | 16.47B | |
| -0.18% | +1.20% | +36.21% | +124.29% | 16.33B | |
| -0.11% | +2.41% | +6.24% | +18.87% | 13.98B | |
| -0.96% | +12.84% | +75.17% | +27.81% | 12.68B | |
| Average | +1.44% | +3.06% | +83.21% | +114.21% | 28.6B | |
| Weighted average by Cap. | +1.86% | +2.31% | +100.97% | +137.09% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | 921M 796M 744M 682M 1.28B 87.63B 1.3B 8.73B 3.43B 43.92B 3.46B 3.38B 145B | 1.4B 1.21B 1.13B 1.04B 1.95B 133B 1.98B 13.28B 5.21B 66.86B 5.26B 5.15B 221B |
| Net income | -590M -510M -477M -437M -822M -56.15B -835M -5.59B -2.19B -28.14B -2.22B -2.17B -93.04B | -319M -276M -257M -236M -444M -30.34B -451M -3.02B -1.19B -15.2B -1.2B -1.17B -50.27B |
| Net Debt | -396M -342M -320M -293M -551M -37.65B -560M -3.75B -1.47B -18.87B -1.49B -1.45B -62.38B | -241M -208M -194M -178M -335M -22.91B -341M -2.28B -895M -11.48B -904M -884M -37.95B |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
